Impacts of the One Big Beautiful Bill Act on the Agriculture and Food Industry
How International Companies Can Prepare for July 9 Tariffs
Foreign Correspondent Podcast | The America First Investment Policy and What it Means for Investors
Hot Topics in International Trade - Tariff Mitigation Strategies
CHPS Podcast Episode 4: Tariffs and Trade Impact
Hot Topics in International Trade Terrified by Tariffs Braumiller Law
Tariffs and Trade Series: What Boards of Directors Need to Know
Tariffs and Trade Series: What Investors Need to Know
Wiley's 2025 Key Trade Developments Series: Trade Remedies
Wiley's 2025 Key Trade Developments Series: U.S.-Mexico-Canada Agreement (USMCA)
Wiley's 2025 Key Trade Developments Series: Tariffs
Compliance Tip of the Day: The Role of Supply Chain and Compliance in Tariffs
Compliance Tip of the Day: Essential Economic Data for Navigating Tariffs
Compliance Tip of the Day: Role of Compliance in Upcoming Trade Wars
Tariffs and Trade Series: Effects on Agriculture Operations and Markets
Tit For Tat US China Trade War
Compliance Tip of the Day: Navigating Uncertainty During Trump’s Tariffs
Daily Compliance News: April 14, 2025, The Cascade of Corruption Edition
Sunday Book Review: April 13, 2025, The Books on Trade and Tariffs Edition
Daily Compliance News: April 11, 2025 The Tariff Rollback Edition
On April 29th, Ambassador Jamieson Greer, U.S. Trade Representative (USTR), issued the 2025 Special 301 Report. In a press release (being quite different in tone from many over the past decade), the USTR stated that "[o]ur...more
Dean Foods, the largest milk company in the U.S., has filed for bankruptcy protection, a “fresh setback to a U.S. dairy industry struggling against declining U.S. milk consumption and rising competition.” Industry experts...more
We Work’s largest investor, SoftBank, is reportedly sketching out plans in which it would drop billions of additional money on the company in return for giving Masa Son control of WeWork “and further sidelin[ing] its founder...more
OxyContin-maker Purdue Pharma and its owners, the Sackler family, reached a deal this week with the state of Oklahoma in which they will pay “$270 million to avoid going to a state court trial over the company’s role in the...more
GE—still in streamlining mode—agreed yesterday to sell its biopharma business to Danaher (current CEO Larry’s Culp’s former company, btw) for a reported $21.4 billion in the form of $21 billion in cash and $400 million in...more